The Spectranetics — Spectranetics — Investor Presentation (January 2016)
20 slides from The Spectranetics's investor presentation, Jan 11, 2016
Slide 1: A Clear Mission: A Look Ahead Management Presentation January 2016
A CLEAR MISSION A Look Ahead Management Presentation January 2016
Slide 2: Safe Harbor Statement
2 | © 2016 Spectranetics All Rights Reserved. Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Y
Slide 3: Spectranetics Growth Driven Company
3 | © 2016 Spectranetics All Rights Reserved. SPECTRANETICS Growth Driven Company • Founded 1984, HQ in Colorado • Listed on NASDAQ in 1992: SPNC • Growth story • Large, growing markets; gaining share • Compelling product portfolio & clinical studies pipeline • ~900 Global teammates, >65 countries
Slide 4: Serving Two Markets
4 | © 2016 Spectranetics All Rights Reserved. Serving Two Markets SPNC MARKET OPPORTUNITY ~$6B ~$0.7B LEAD MANAGEMENT~$5.3B VASCULAR INTERVENTION
Slide 5: Vascular Markets: PAD and CAD
5 | © 2016 Spectranetics All Rights Reserved. 1.5M procedures/year 25M in the EU & U.S. alone >200M afflicted globally 1.7M procedures/year $190B healthcare costs >500M EU & U.S. with ≥1 CVD major risk factor PAD: Underpenetrated & Growing CAD: Large Established Market 1.1M 600K • Diagnosis and trea
Slide 6: Peripheral Artery Disease
6 | © 2016 Spectranetics All Rights Reserved. PERIPHERAL ARTERY DISEASE 6 34M OPPORTUNITY: Diagnosis and treatment standards needed Strong healthcare economics 875,000 PTA, Stents 250,000 Bypass 250,000 Amputation 125,000 Atherectomy >200M People Living with PAD Globally 25M EU & US alone* $1.7B Mar
Slide 7: Lead Management Market Characteristics
7 | © 2016 Spectranetics All Rights Reserved. Market Characteristics Large, growing, underpenetrated market Patients are implanted younger and living longer = more device replacements Sicker patients, aging devices = 320% increase in infection rate over a 7-year period Lead management = cent
Slide 8: Life & Limb Saving Portfolio
8 | © 2016 Spectranetics All Rights Reserved. LIFE & LIMB SAVING PORTFOLIOSolving Complex Challenges Lead Management – Laser & Mechanical Tools Vascular Intervention – Cross - Prep - Treat * * Not approved for use in the U.S. *
Slide 9: The Road Ahead: Robust Pipeline
9 | © 2016 Spectranetics All Rights Reserved. THE ROAD AHEADRobust Pipeline 2015 • EU Stellarex ATK • Turbo Power • AngioSculpt 7mm & 8mm 2016 • Bridge to Surgery • Initiate 10,000 patient clinical studies… • EU DCBs – Stellarex BTK & AngioSculptX 2017 • US Stellarex ATK • Nexcimer – Next Gen Laser
Slide 10: Pipeline Highlights
10 | © 2016 Spectranetics All Rights Reserved. INTRODUCING THE STANDARD FOR ISR. PIPELINE HIGHLIGHTS “Most significant innovation in lead management since laser” –Dr. Jude Clancy Yale Medical Group * Not approved for use in the U.S. *
Slide 11: DCB Program
11 | © 2016 Spectranetics All Rights Reserved. DCB PROGRAM • Top tier first-in-human clinical data and performance • Completed enrollment of ILLUMENATE program – Five clinical trials enrolling over 1100 pts – 12-month data to be presented in 2016 • EU launch progressing nicely • Stellarex US launch
Slide 12: DCB Program
12 | © 2016 Spectranetics All Rights Reserved. DCB PROGRAM * Not approved for use in the U.S. * “… ILLUMENATE FIH study indicates Stellarex as a distinguished second generation DCB technology able to combine low drug dose with amongst best reported clinical outcomes up to 2 years” - Dr. Thomas Zelle
Slide 13: ILLUMENATE Data Release
13 | © 2016 Spectranetics All Rights Reserved. ILLUMENATE DATA RELEASE Next 12 months April 2016 ILLUMENATE Global 12 month interim data September 2016 ILLUMENATE EU RCT 12 month data October 2016 ILLUMENATE US Pivotal 12 month data January 2017 ILLUMENATE Global Registry 12 month data January 2016
Slide 14: Looking Back: Track Record of Growth
14 | © 2016 Spectranetics All Rights Reserved. 25 50 75 100 125 150 175 200 225 250 275 2011 2012 2013 2014 2015 Outlook Demonstrated track record of growth Large, growing markets, taking share Compelling clinical data Attractive innovation pipeline Expanding global footprint LOOKING BACK (i n
Slide 15: Looking Ahead
15 | © 2016 Spectranetics All Rights Reserved. LOOKING AHEAD
Slide 16: © Spectranetics:
© Spectranetics:
Slide 17: Differentiated Portfolio
17 | © 2016 Spectranetics All Rights Reserved. DIFFERENTIATED PORTFOLIO Solving Complex Challenges Cross Prep •Quick-Cross •Quick-Cross Select •Quick-Cross Extreme •Quick-Cross Capture •Turbo-Elite •Quick-Access •Turbo-Elite •Turbo-Power •ELCA •AngioSculpt PTA •AngioSculpt PTCA •Quick-Cat •Stellarex
Slide 18: Comprehensive Toolkit Addressing Physician Needs
18 | © 2016 Spectranetics All Rights Reserved. COMPREHENSIVE TOOLKIT Addressing Physician Needs Laser • Broadened portfolio in mid-2015 • Gaining share • Continued expansion in 2016 • LLD locks onto inner length of lead • First choice before using powered sheath • Superior procedural success vs. com
Slide 19: Global Growth: Accelerating the Market Opportunity
19 | © 2016 Spectranetics All Rights Reserved. India Russia China Brazil Germany Japan GLOBAL GROWTHAccelerating the Market Opportunity • Separate LM/VI salesforces • Take share with mechanical tools • Stellarex® launch • AngioSculpt performing well • Submit Peripheral atherectomy Shonin 2016 Launch
Slide 20: History & Future Goals
20 | © 2016 Spectranetics All Rights Reserved. HISTORY & FUTURE Goals Next 4-5 Years • 2X Organic Revenue • DCBs, Atherectomy, Bridge to Surgery, Global Expansion • Gross Margin • 50 bps improvement / year • Pipeline • Robust product and clinical data pipeline • Profitability • Growth as a foundatio